DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/khf2lr/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering.

Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches

The global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.2%.

Out of the eight major markets the US, Canada, France, Germany, Italy, Spain, the UK and Japan the majority of HBV vaccine sales will take place in the US, which will boast a higher CAGR of 3.4% and expand its market share from 55% to 61.7% during the forecast period. The US will be followed by Canada and the five European countries, with expected CAGRs of 1% and 0.5%, respectively.

The growth in HBV vaccine sales will result from the launch of Dynavax Technologies' Heplisav and Sanofi Pasteur MSD's Hexyon, with peak-year sales anticipated to reach $85 million and $520 million, respectively.

Christopher Pace, Ph.D., The report Analyst covering Infectious Diseases, says: Dynavax hopes to leverage Heplisav's superior immunogenicity and dosing regimen to increase HBV vaccine uptake in the adult market. On the other hand, Sanofi Pasteur MSD is positioning Hexyon to be the first fully liquid pediatric hexavalent vaccine.

However, the authors believe that inadequate HBV vaccination coverage rates in certain high-risk populations represents one of the most important unmet needs in the marketplace.

Pace says: In the pediatric segment, companies are leveraging combination vaccines to increase HBV vaccine uptake, while improved dosing regimens are necessary to increase vaccination coverage rates in adults.

For both children and adults, these companies must ensure that physicians understand immunization recommendations and are able to effectively identify patients. Overall, ensuring high coverage rates will be essential to the commercial success of HBV vaccines during the forecast period.

This report provides an overview of hepatitis B virus (HBV), including etiology, general symptoms from infection, and country-specific immunization recommendations and vaccination coverage data. It also gives annualized HBV vaccine market revenue, annual cost of vaccination and treatment usage pattern data from 2012 to 2022.

Key Topics Covered:

List of Tables

List of Figures

Introduction

Disease Overview

Vaccination Recommendations and Coverage Rates

Competitive Assessment

Opportunity and Unmet Need

Pipeline Assessment

Current and Future Players

Market Outlook

Appendix

Companies Mentioned

GSK

Merck

Sanofi

Kaketsuken

Dynavax Technologies

For more information visit http://www.researchandmarkets.com/research/khf2lr/pharmapoint

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.